

City of Mississauga
Economic Development Office
300 City Centre Drive
MISSISSAUGA ON L5B 3C1
mississauga.ca

December 1, 2022

Re: PMPRB draft Guidelines

To Whom It May Concern,

On behalf of the City of Mississauga's Economic Development Office (EDO), this letter is to express concern over the potential impact the new draft Guidelines released by PMPRB on October 6, 2022, could have on the life sciences industry, particularly the pharmaceutical sector in Mississauga.

Mississauga is home to a thriving life sciences sector, the second largest in Canada, featuring over 470 companies – many are global leaders in innovative medicines – employing over 25,000 people. Within this sector, over 40 pharmaceutical companies in Mississauga contribute significantly to our local economy, creating jobs, paying taxes, and helping us grow the life sciences sector within our City.

Our Mayor has previously raised concern regarding the changes to PMPRB's regulations and the resulting impact on the availability of new medicines, employment, and research investments in Mississauga and Canada. More recently, in speaking with representatives of the Mississauga pharmaceutical industry, we understand that there is a continued concern following the release of the new draft Guidelines.

While PMPRB believes its approach is flexible and pragmatic, the industry views the draft Guidelines as lacking clarity and predictability, which they require when making new product launch decisions. This uncertainty could negatively influence businesses' decisions concerning investing and bringing innovative products to the market in Canada, affecting the timely access to medicines for Canadian patients and stifling the growth of this strategic sector.

We are concerned about the impact these draft guidelines could have on Mississauga's economy, which has benefited from significant investment by the pharmaceutical industry. We respectfully ask that the PMPRB revisit the Guidelines and consult with industry and stakeholders to address their need for clarity and predictability. Clear and predictable guidelines will enable businesses to make informed investment decisions and in turn, create a more welcoming and competitive environment for the Life Sciences industry to invest and grow.

Thank you for providing the opportunity to provide feedback.

Sincerely,



Christina Kakaflikas
Director, Economic Development